Market Cap : 272.65 B | Enterprise Value : 283.5 B | PE Ratio : 9.51 | PB Ratio : 3.13 |
---|
NYSE:PFE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:PFE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Pfizer's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2022 was 26.48%.
As of today (2022-08-18), Pfizer's WACC % is 5.58%. Pfizer's ROIC % is 18.97% (calculated using TTM income statement data). Pfizer generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
The historical data trend for Pfizer's ROIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Pfizer's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Pfizer's ROIC % distribution charts can be found below:
* The bar in red indicates where Pfizer's ROIC % falls into.
Pfizer's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2021 is calculated as:
ROIC % (A: Dec. 2021 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (A: Dec. 2020 ) | + | Invested Capital (A: Dec. 2021 )) | / count ) |
= | 20235 * ( 1 - 7.62% ) | / | ( (137588 | + | 155361) | / 2 ) |
= | 18693.093 | / | 146474.5 | |||
= | 12.76 % |
where
Invested Capital | (A: Dec. 2020 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 154229 | - | 7494 | - | ( 12223 | - | max(0, 25920 | - | 35067 | + | 12223 | )) |
= | 137588 |
Invested Capital | (A: Dec. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 181476 | - | 9093 | - | ( 31069 | - | max(0, 42671 | - | 59693 | + | 31069 | )) |
= | 155361 |
Pfizer's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2022 is calculated as:
ROIC % (Q: Jun. 2022 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Mar. 2022 ) | + | Invested Capital (Q: Jun. 2022 )) | / count ) |
= | 49636 * ( 1 - 13.72% ) | / | ( (160006 | + | 163431) | / 2 ) |
= | 42825.9408 | / | 161718.5 | |||
= | 26.48 % |
where
Invested Capital | (Q: Mar. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 183841 | - | 8683 | - | ( 23897 | - | max(0, 39268 | - | 54420 | + | 23897 | )) |
= | 160006 |
Invested Capital | (Q: Jun. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 195290 | - | 11803 | - | ( 33304 | - | max(0, 47410 | - | 67466 | + | 33304 | )) |
= | 163431 |
Note: The Operating Income data used here is four times the quarterly (Jun. 2022) data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Pfizer's WACC % is 5.58%. Pfizer's ROIC % is 18.97% (calculated using TTM income statement data). Pfizer generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases. Pfizer earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Thank you for viewing the detailed overview of Pfizer's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Denton David M | officer: Chief Financial Officer & EVP | 1000 LOWE'S BOULEVARD MOORESVILLE NC 28117 |
Pao William | officer: Executive Vice President | C/O CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017 |
Mcdermott Michael | officer: Executive Vice President | C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET 235 EAST 42ND STREET NY 10017 |
Malik Aamir | officer: Executive Vice President | C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017 |
Carapezzi William R Jr | officer: Executive Vice President | 600 MOUNTAIN AVENUE MURRAY HILL NJ 07921 |
Sahni Payal | officer: Executive Vice President | ATTN: PFIZER CORP. SECRETARY 235 EAST 42ND ST. NEW YORK NY 10017 |
Desmond-hellmann Susan | director | 513 PARNASSUS AVENUE S126 SAN FRANCISCO CA 94143 |
Hockfield Susan | director | GENERAL ELECTRIC COMPANY 41 FARNSWORTH STREET BOSTON MA 02210 |
Damico Jennifer B. | officer: SVP & Controller | C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017 |
Quincey James | director | THE COCA-COLA COMPANY ONE COCA-COLA PLAZA ATLANTA GA 30313 |
Gottlieb Scott | director | MOLECULAR INSIGHT PHARMACEUTICALS 160 SECOND STREET CAMBRIDGE MA 02142 |
Fonseca Lidia | officer: Executive Vice President | 358 SOUTH MAIN STREET BURLINGTON NC 27215 |
Goettler Michael | officer: Group President | 1000 MYLAN BOULEVARD CANONSBURG PA 15317 |
Rogers Dawn | officer: Executive Vice President | 235 EAST 42ND STREET NEW YORK NY 10017 |
Littman Dan R. | director | ATTN: CORPORATE SECRETARY PFIZER INC. 235 E. 42ND ST NEW YORK NY 10017 |
Other Sources
By Zacks 2022-03-23
By Zacks 2022-03-30
By Zacks 2022-04-01
By Zacks 2022-03-22
By Fool 2022-04-05
By Zacks 2022-03-30
By Zacks 2022-03-25
By Zacks 2022-03-30
By Zacks 2022-03-28
By tipranks.com 2022-03-25
By Zacks 2022-03-23
By tipranks.com 2022-03-25
By Zacks 2022-04-04
By Zacks 2022-03-25